Last reviewed · How we verify

NCT01274325

Comparison of Anti-inflammatory Effects of Seroflo 125 Inhaler With Seretide Evohaler(25/125) in Patients With Asthma

Completed Phase 3 Last updated 9 September 2013
What this trial tests

Phase 3 trial testing Sereflo in Asthma in 51 participants. Completed in 1 July 2013.

Timeline
1 February 2011
Primary endpoint
1 April 2013
1 July 2013

Quick facts

Lead sponsorMahidol University
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingquadruple
Primary purposetreatment
Enrollment51
Start date1 February 2011
Primary completion1 April 2013
Estimated completion1 July 2013
Sites2 locations across Thailand

Drugs / interventions tested

Conditions studied

Sponsor

Mahidol University

Who can join

Adults 18 to 80, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is to test hypothesis if Sereflo (ICS/LABA) could reduce airway inflammation in asthmatic patients in the same as Seretide.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

Other Mahidol University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01274325.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing